ArticleAsian Pacific journal of cancer prevention : APJCP2026
Significance of Total Colonoscopy Based on the Outcome of Advanced Colorectal Cancer in Older Individuals.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the increase in Japan's aging population, the number of total colonoscopies (TCS) performed in individuals aged over 80 years is rising. However, TCS carries an increased risk of complications in older individuals, raising concerns about its utility in this population. This study aimed to evaluate the clinical value of TCS in older individuals diagnosed with advanced colorectal cancer (CRC) at our institution. MATERIALS AND
methodsWe conducted a retrospective review of patients aged ≥80 years who underwent TCS between January 2010 and December 2021. Patients diagnosed with advanced CRC were categorized into symptomatic and asymptomatic groups based on the presence or absence of symptoms. The groups were compared in terms of clinical characteristics, pathological features, and long-term outcomes.
resultsAmong 4,130 older patients who underwent TCS, 297 (7.2%) were diagnosed with advanced CRC. Of these, 221 (74%) were symptomatic, and 76 (26%) were asymptomatic. Compared with symptomatic patients, asymptomatic patients had significantly higher body mass index (23.6 vs. 21.5 kg/m²), serum albumin levels (3.7 vs. 3.5 g/dL), and lower carcinoembryonic antigen (CEA; 3.9 vs. 5.6 ng/mL) and carbohydrate antigen 19-9 (CA19-9; 13.4 vs. 19.7 U/mL) levels (all p<0.05). The asymptomatic group also had a higher rate of early-stage disease (68.4% vs. 36.2%) and a greater history of prior TCS (21.1% vs. 5.4%, p<0.001). Five-year overall and disease-specific survival rates were significantly higher in the asymptomatic group (68.3% and 88.3%, respectively) compared to the symptomatic group (38.7% and 65.5%) (p<0.001). No severe complications, such as perforation, were observed.
conclusionTCS facilitates early detection and improves prognosis in older patients with advanced CRC, supporting its use in appropriately selected individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.